Validation of clinical risk tools for recurrent Clostridioides difficile infection
Open Access
- 9 May 2024
- journal article
- research article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (9) , 1064-1072
Abstract
Objective: We sought to validate available tools for predicting recurrent C. difficile infection (CDI) including recurrence risk scores (by Larrainzar-Coghen, Reveles, D’Agostino, Cobo, and Eyre et al) alongside consensus guidelines risk criteria, the leading severity score (ATLAS), and PCR cycle threshold (as marker of fecal organism burden) using electronic medical records.Design: Retrospective cohort study validating previously described tools.Setting: Tertiary care academic hospital.Patients: Hospitalized adult patients with CDI at University of Virginia Medical Center.Methods: Risk scores were calculated within ±48 hours of index CDI diagnosis using a large retrospective cohort of 1,519 inpatient infections spanning 7 years and compared using area under the receiver operating characteristic curve (AUROC) and the DeLong test. Recurrent CDI events (defined as a repeat positive test or symptom relapse within 60 days requiring retreatment) were confirmed by clinician chart review.Results: Reveles et al tool achieved the highest AUROC of 0.523 (and 0.537 among a subcohort of 1,230 patients with their first occurrence of CDI), which was not substantially better than other tools including the current IDSA/SHEA C. difficile guidelines or PCR cycle threshold (AUROC: 0.564), regardless of prior infection history.Conclusions: All tools performed poorly for predicting recurrent C. difficile infection (AUROC range: 0.488–0.564), especially among patients with a prior history of infection (AUROC range: 0.436–0.591). Future studies may benefit from considering novel biomarkers and/or higher-dimensional models that could augment or replace existing tools that underperform.Keywords
This publication has 38 references indexed in Scilit:
- Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western AustraliaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2023
- Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United StatesInfectious Diseases and Therapy, 2021
- Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI scoreInternational Journal of Antimicrobial Agents, 2018
- Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of VeteransPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Overdiagnosis ofClostridium difficileInfection in the Molecular Test EraJAMA Internal Medicine, 2015
- Risk Factors for Recurrent Clostridium difficile Infection in Children: A Nested Case-Control StudyThe Journal of Pediatrics, 2015
- Development and validation of a recurrent Clostridium difficile risk‐prediction modelJournal of Hospital Medicine, 2014
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Continuous versus Categorical Data for ROC AnalysisAcademic Radiology, 2001